COMPETITIVE DOMAIN ANTIBODY FORMATS THAT BIND INTERLEUKIN 1 RECEPTOR TYPE 1

The invention relates to dAb monomers that bind IL-1R1 and inhibit binding of IL-1 (e.g., IL-1E and/or IL-1F) and IL-1ra to IL-1R1, and to ligands comprising such dAb monomers. The invention relates to protease resistand dAb monomers, and to ligands comprising protease resistant dAb monomers. The in...

Full description

Saved in:
Bibliographic Details
Main Authors DREW PHILIP D, DE WILDT RUDOLF M. T, TOMLINSON IAN M, BASRAN AMRIK
Format Patent
LanguageEnglish
Published 21.08.2008
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The invention relates to dAb monomers that bind IL-1R1 and inhibit binding of IL-1 (e.g., IL-1E and/or IL-1F) and IL-1ra to IL-1R1, and to ligands comprising such dAb monomers. The invention relates to protease resistand dAb monomers, and to ligands comprising protease resistant dAb monomers. The invention also relates to nucleic acids including vectors that encode the dAb monomers and ligand, to host cells that comprise the nucleic acids and to method for producing a dAb monomer or ligand. The invention also relates to pharmaceutical compositions that comprise the dAb monomers or ligands, and to therapeutic methods that comprise administering a dAb monomer of ligand.
Bibliography:Application Number: KR20087015943